Modeling psychiatric disorders with patient-derived iPSCs

Zhexing Wen; Kimberly M Christian; Hongjun Song; Guo-li Ming

doi:10.1016/j.conb.2015.11.003

Modeling psychiatric disorders with patient-derived iPSCs

Curr Opin Neurobiol. 2016 Feb:36:118-27. doi: 10.1016/j.conb.2015.11.003. Epub 2015 Dec 17.

Authors

Zhexing Wen¹, Kimberly M Christian¹, Hongjun Song², Guo-li Ming³

Affiliations

¹ Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
² Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
³ Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Electronic address: gming1@jhmi.edu.

Abstract

Psychiatric disorders are heterogeneous disorders characterized by complex genetics, variable symptomatology, and anatomically distributed pathology, all of which present challenges for effective treatment. Current treatments are often blunt tools used to ameliorate the most severe symptoms, often at the risk of disrupting functional neural systems, thus there is a pressing need to develop rational therapeutics. Induced pluripotent stem cells (iPSCs) reprogrammed from patient somatic cells offer an unprecedented opportunity to recapitulate both normal and pathologic human tissue and organ development, and provides new approaches for understanding disease mechanisms and for drug discovery with higher predictability of their effects in humans. Here we review recent progress and challenges in using human iPSCs for modeling neuropsychiatric disorders and developing novel therapeutic strategies.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Autism Spectrum Disorder / genetics
Autism Spectrum Disorder / physiopathology
Autistic Disorder / genetics
Autistic Disorder / physiopathology
Bipolar Disorder / genetics
Bipolar Disorder / physiopathology
Chromosome Deletion
Chromosome Disorders / genetics
Chromosome Disorders / physiopathology
Chromosomes, Human, Pair 22 / genetics
Depressive Disorder, Major / genetics
Depressive Disorder, Major / physiopathology
Humans
Induced Pluripotent Stem Cells*
Long QT Syndrome / genetics
Long QT Syndrome / physiopathology
Mental Disorders / genetics*
Mental Disorders / physiopathology
Models, Neurological
Rett Syndrome / genetics
Rett Syndrome / physiopathology
Schizophrenia / genetics
Schizophrenia / physiopathology
Syndactyly / genetics
Syndactyly / physiopathology
Williams Syndrome / genetics
Williams Syndrome / physiopathology

Supplementary concepts

Telomeric 22q13 Monosomy Syndrome
Timothy syndrome

Abstract

Publication types

MeSH terms

Supplementary concepts

Grants and funding